Novo Nordisk earns 72 billion kroner

In the first nine months of the year, Novo Nordisk has earned 72.8 billion kroner, a surge of 18% compared to the same period in the previous year. Its revenue reached almost 205 billion kroner, a 23% increase from the year before. Growth is largely attributed to the sale of GLP-1 drugs for diabetes and obesity. CEO Lars Fruergaard Jørgensen expressed satisfaction with the company’s 2024 performance, noting the high demand for GLP-1-based drugs and an increased number of patients treated. Ozempic remains the best-selling drug, with sales of 86.5 billion kroner, up by 32%. Wegovy’s sales also soared, with a 76% increase to 38.3 billion kroner. Novo Nordisk has narrowed its full-year expectations, now anticipating revenue growth of 23-27% and operating profit growth of 21-27% in local currency.